Dr Lal Pathlabs Ltd (LALPATHLAB)
🎯 Key Takeaways
- Revenue grew 13.5% QoQ to ₹798 in Q1FY27.
- Market Cap
- ₹33,320
- P/E Ratio
- 61.0
- P/B Ratio
- 13.28
- ROE
- 21.6%
- ROCE
- 29.6%
- Debt/Equity
- 0.00
- Div Yield
- 1.23%
- Promoter
- 53.2%
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 731 | 660 | 703 | 798 |
| Operating Profit | 184 | 137 | 142 | 203 |
| OPM % | 25.1% | 20.8% | 20.2% | 25.5% |
| Net Profit | 152 | 91 | 132 | 171 |
| EPS | ₹18.05 | ₹5.42 | ₹7.86 | ₹10.15 |
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 84 | 84 | 168 | 84 |
| Reserves | 2,089 | 1,918 | 2,341 | 2,304 |
| Borrowings | 157 | 199 | 0 | 156 |
| Total Liabilities | 2,717 | 2,598 | 3,146 | 2,959 |
| Fixed Assets | 369 | 361 | 1,225 | 463 |
| Investments | 327 | 289 | 455 | 486 |
| Total Assets | 2,717 | 2,598 | 3,146 | 2,959 |
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +636 |
| Investing | -422 |
| Financing | -264 |
| Net Cash Flow | -50 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 53.2% | 53.2% | 53.2% | 53.2% |
| FII | 21.9% | 20.3% | 17.2% | 17.4% |
| DII | 18.5% | 19.2% | 21.4% | 21.6% |
| Public | 5.2% | 5.8% | 6.5% | 6.3% |
| # Shareholders | 1,12,703 | 1,16,167 | 1,14,527 | 1,11,037 |
⚖️ Peer Comparison — Healthcare
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| APOLLOHOSP | 1.17 L Cr | 56.0 | 22.1% | — | 0.60 |
| MANIPALHOS | 93,221 | — | — | — | 1.25 |
| MAXHEALTH | 90,482 | 62.0 | 14.4% | — | 0.27 |
| ASTERDM | 60,634 | 112.6 | 12.9% | — | 0.17 |
| FORTIS | 57,996 | 55.4 | 13.3% | — | 0.29 |
| MEDANTA | 36,689 | 65.9 | 21.9% | — | 0.10 |
| NH | 36,640 | 44.6 | 13.7% | — | 1.07 |
| LALPATHLAB | 33,320 | 47.9 | 29.6% | — | 0.00 |
| KIMS | 31,423 | 146.7 | 9.7% | — | 1.44 |
| POLYMED | 16,977 | 53.9 | 15.1% | — | 0.06 |
🔗 Peer Stock Analyses
📋 Recent Filings
- 🔴 Corporate Action2026-10-01Dr Lal Pathlabs announced completion of its acquisition of SN Genelab Private Limited on October 1, 2026, finalizing a previously approved deal. The t…
- 🔴 Corporate Action2026-09-26Dr Lal PathLabs announced completion of its Dubai subsidiary's acquisition of an 80% stake in Sunshine Healthcare Limited in Ghana, finalizing a deal …
- 🟡 Board Meeting2026-09-25The board announced a meeting on November 4, 2026 to approve unaudited standalone and consolidated financial results for the quarter and half-year end…
- Announcement2026-09-25Dr Lal Pathlabs announced a board meeting on November 4, 2026, to approve Q3 and H1 FY27 financial results, with trading closed from October 1 to Nove…
- 🟡 Board Meeting2026-09-24Dr Lal Pathlabs announced on September 24, 2026, that its board approved acquiring a 70% stake in SN Genelab Private Limited for up to INR 168 Crores …
- 🔴 Corporate Action2026-09-24Dr Lal Pathlabs announced acquisition of 70% stake in SN Genelab Private Limited for up to INR 168 crores cash plus INR 31.5 crores performance-linked…
- 🔴 Corporate Action2026-08-27Dr Lal Pathlabs announced completion of its 30% stake acquisition in Neuome Technologies Private Limited on August 27, 2026, making Neuome an associat…
- 🟡 related party transaction2026-08-19Dr Lal PathLabs announced incorporation of Dr Lal PathLabs Indomed LLC in Tashkent, Uzbekistan, with its Dubai subsidiary subscribing 70% of the new e…
- 🟡 Board Meeting2026-08-06The Board approved the allotment of 211,050 equity shares under the ESOP Plan 2022, increasing paid-up capital to INR 1,67.84 crores across 16,78,48,8…
- 🔴 Financial Results2026-07-30Dr. Lal PathLabs reported Q1 FY27 revenue of **[amount context mismatch] crores**, up **19.1% YoY**, driven by **8.2% patient volume growth** and **25…
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-10-01.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when LALPATHLAB files new disclosures
Track LALPATHLAB filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track LALPATHLAB — FreeFree account · 2 AI queries/day